This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): T-705, Avigan (Japan)
Favipiravir (T-705) is a novel anti-viral compound that works against a different viral enzyme target than either of the approved antiviral agents used to treat people who have become ill with influenza.
Non-clinical trials have confirmed that, because of its characteristics as a viral RNA polymerase inhibitor, T-705 is efficacious against type A,-, B-, and C-type seasonal flu viruses (including the swine influenza virus) as well as against other diverse types and subtypes of viruses, such as virus resistant to neuraminidase inhibitors and highly pathogenic avian virus.
Favipiravir was originally developed by Toyoma Chemical, a subsidiary of FUJIFILM.
By March 2012, MediVector had acquired rights to develop the compound.
Fujifilm and Zhejuang Hisun
In June 2016, Fujifilm Corporation announced that it signed a patent license agreement concerning Favipiravir with Zhejiang Hisun Pharmaceutical. Under this agreement, Fujifilm grants Hisun Pharmaceutical a license to use its Favipiravir-related patents in China to develop, manufacture and market an anti-influenza drug in China. Fujifilm will receive a lump-sum payment and loyalties once such a influenza drug is introduced to the market.
Partners: Toyama Chemical Co., Ltd. Zhejiang Hisun Pharmaceutical Co. Ltd.
Additional information available to subscribers only: